Arena Provides Updates on Carcinogenicity Issues Relating to Lorcaserin (ARNA, $1.91)Wednesday, August 10, 2011 · 1:22 pm |
|
Implications for Lorquess From FDA Request for Extremely Large Cardiovascular Outcomes Study for Orexigen's Contrave (ARNA, $1.31)Sunday, June 5, 2011 · 3:38 pm |
|
FDA Advisory Committee Vote on Lorcaserin is Negative (ARNA, $3.74)Saturday, June 4, 2011 · 7:39 am |
|
Trying to Define Path Forward for Lorcaserin with FDA (ARNA,$1.49)Saturday, June 4, 2011 · 7:34 am |
|
There are 4 reports on file. |